Literature DB >> 10631193

Hyperuricemia in severe pulmonary hypertension.

M A Voelkel1, K M Wynne, D B Badesch, B M Groves, N F Voelkel.   

Abstract

STUDY
OBJECTIVE: Hyperuricemia occurs frequently in patients with myeloproliferative and lymphoproliferative disorders and in patients with congenital heart disease associated with polycythemia. Whether hyperuricemia is common in patients with severe pulmonary hypertension is not known. DESIGN, PATIENTS, MEASUREMENTS: In the Pulmonary Hypertension Center at the University of Colorado Health Sciences Center between September 1991 and August 1997, 442 consecutive patients were evaluated with right heart catheterization; 191 patients also had a measurement of the serum uric acid (UA) in close temporal proximity to the hemodynamic evaluation.
RESULTS: Of the 191 patients with a complete data set, 99 patients had primary pulmonary hypertension (PPH) and 92 had secondary pulmonary hypertension. For the entire cohort with severe pulmonary hypertension (n = 191), there was a positive correlation between the natural logarithm of the serum UA (lnUA) and the mean right atrial pressure (RAP; r = 0.47; p < 0.001). When analyzed separately, the correlation between lnUA and RAP was stronger in the patients with PPH (r = 0.642; p < 0.001). This correlation cannot be explained by diuretic use or impaired hepatocellular function. Neither mean pulmonary artery pressure nor cardiac output was as well correlated with the RAP when compared with the lnUA. Some patients with PPH had serum UA measurements repeated during treatment with chronic IV prostacyclin infusion. Eleven of these 18 patients (61%) demonstrated a decrease in serum UA during prostacyclin treatment.
CONCLUSION: There is a positive correlation between the RAP elevation and the serum UA levels in patients with PPH. Serum UA levels drop in some, but not all PPH patients during chronic prostacyclin infusion therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10631193     DOI: 10.1378/chest.117.1.19

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  28 in total

1.  Laboratory and echocardiography markers in sickle cell patients with leg ulcers.

Authors:  Caterina P Minniti; James G Taylor; Mariana Hildesheim; Patricia O'Neal; Jonathan Wilson; Oswaldo Castro; Victor R Gordeuk; Gregory J Kato
Journal:  Am J Hematol       Date:  2011-05-31       Impact factor: 10.047

Review 2.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

Review 3.  Biomarkers in pulmonary arterial hypertension.

Authors:  Julie L Rosenthal; Miriam S Jacob
Journal:  Curr Heart Fail Rep       Date:  2014-12

Review 4.  Pulmonary hypertension: diagnosis, imaging techniques, and novel therapies.

Authors:  Alan B Goldberg; Wojciech Mazur; Dinesh K Kalra
Journal:  Cardiovasc Diagn Ther       Date:  2017-08

Review 5.  [Hyperuricemia - more than gout : Impact on cardiovascular risk and renal insufficiency].

Authors:  L Sellin; J T Kielstein; K de Groot
Journal:  Z Rheumatol       Date:  2015-05       Impact factor: 1.372

6.  Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study.

Authors:  Theodoros Dimitroulas; Georgios Giannakoulas; Hariklia Dimitroula; Tilemahos Sfetsios; Despina Parcharidou; Haralambos Karvounis; Loukas Settas
Journal:  Rheumatol Int       Date:  2010-07-25       Impact factor: 2.631

7.  Relationship between serum uric acid levels and ventricular function in patients with idiopathic pulmonary hypertension.

Authors:  Chun-Yan Zhang; Long-Le Ma; Le-Xin Wang
Journal:  Exp Clin Cardiol       Date:  2013

8.  Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells.

Authors:  Sergey Zharikov; Karina Krotova; Hanbo Hu; Chris Baylis; Richard J Johnson; Edward R Block; Jawaharlal Patel
Journal:  Am J Physiol Cell Physiol       Date:  2008-09-10       Impact factor: 4.249

9.  2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension.

Authors:  Chih-Hsin Hsu; Wan-Jing Ho; Wei-Chun Huang; Yu-Wei Chiu; Tsu-Shiu Hsu; Ping-Hung Kuo; Hsao-Hsun Hsu; Jia-Kan Chang; Chin-Chang Cheng; Chao-Lun Lai; Kae-Woei Liang; Shoa-Lin Lin; Hsao-Hsun Sung; Wei-Chuan Tsai; Ken-Pen Weng; Kai-Sheng Hsieh; Wei-Hsian Yin; Shing-Jong Lin; Kuo-Yang Wang
Journal:  Acta Cardiol Sin       Date:  2014-09       Impact factor: 2.672

10.  Could uric acid be a modifiable risk factor in subjects with pulmonary hypertension?

Authors:  Sergey I Zharikov; Erik R Swenson; Miguel Lanaspa; Edward R Block; Jawaharlal M Patel; Richard J Johnson
Journal:  Med Hypotheses       Date:  2010-01-12       Impact factor: 1.538

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.